| Modeling group | Validation group | ||
---|---|---|---|---|
 | IgAN | Non-IgAN | IgAN | Non-IgAN |
Number | 58 | 63 | 93 | 87 |
Age (years) | 35.6 ± 12.4 | 39.7 ± 15.3 | 32.8 ± 11.6 b | 43.7 ± 15.7 b |
Male : female | 39:19 | 33:30 | 53:40 | 48:39 |
Hypertension (%) | 28 (48.3%) | 28 (44.4%) | 45 (48.9%) | 50 (57.5%) |
Body mass index (kg/m2) | 24.9 ± 3.7 | 24.8 ± 4.0 | 24.1 ± 4.2 | 25.2 ± 4.3 |
Manifestation | ||||
Chronic nephritis syndrome (%) | 44 (75.9%)a | 23 (36.5%)a | 75 (80.6%)a | 31 (35.6%)a |
Nephrotic syndrome (%) | 10 (17.2%)a | 33 (52.4%)a | 10 (10.8%)a | 51 (58.6%)a |
Isolated proteinuria or hematuria (%) | 4 (6.9%)a | 7 (11.1%)a | 8 (8.6%)a | 5 (5.7%)a |
Renal function | ||||
Normal (%) | 43 (74.1%) | 48 (76.2%) | 67 (72.0%) | 69 (79.3%) |
Chronic renal insufficiency (%) | 15 (25.9%) | 11 (17.5%) | 25 (26.9%) | 14 (16.1%) |
Acute renal insufficiency (%) | 0 | 4 (6.3%) | 1 (1.1%) | 4 (4.6%) |